P-0051 - Gastric adenocarcinoma: Are there histological and epidemiological differences by gender?

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Gastric Cancer
Cancer Aetiology, Epidemiology, Prevention
Pathology/Molecular Biology
Presenter German Calderillo
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors A. Meneses
  • Instituto Nacional de Cancerologia, Tlalpan/MX

Abstract

Introduction

Gastric cancer is a common malignancy in Latin America, Asia and some countries in Europe with high mortality. Adenocarcinoma gastric is more frequent in men, but has not determined that they have different clinical and histological features with possible difference in prognosis.

Methods

A retrospective analysis of patients diagnosed with gastric adenocarcinoma evaluated for the Medical Oncology Service from September 1998 to December 2012. A descriptive and comparative analysis of men (arm A) versus women (arm B). SPSS version 11 was used.

Results

We analyzed 1338 patients diagnosed with gastric adenocarcinoma, 587 were women (43.9%) with a mean age of 52.2 (+ 13.4) years and 751 men (56.1%) with a mean age of 55.8 (+13.6) years (p <0.0001). By age group there are 117 (19.9%) women with aged 40 years or less versus 109 (14.5%) men. Histological features of the women were: diffuse type in 50% (n = 294), intestinal type in 20.6% (n = 121), mixed in 4.6% (n = 27), signet ring cells in 57.2% (n = 336) and poorly differentiated in 74.8% (n = 439) versus of the men 40.8% (n = 307, p < 0.05), 35.3% (n = 265, p < 0.05), 4.9% (n = 37, p = ns), 37.8% (n = 284, p < 0.05) and 63% (n = 473, p < 0.05) respectively. For the primary tumor site, in the men esophageal gastric junction were in 18.8% (n= 141) versus 8.3% (n = 49) in women (p < 0.05). For extent of disease, there were no differences between for gender. Stage I-III was 30.8% (n = 181) in women for 33.8% (n = 254) in men. Stage IV were 65.7% (n = 386) in women versus 62.6% (n = 470) in men. The principal sites of metastases were: peritoneal carcinomatosis 46.3% (n = 170), ascitis 19% (n = 70), liver 20.1% (n = 74), retroperitoneum 13.3% (n = 49), neck 8.4% (n = 31), lung 6.5% (n = 24), mediastinum 3.2% (n = 12) and bone 2.7% (n = 10) in women versus 41.6% (n = 188, p = ns), 19% (n = 86, p = ns), 31.5% (n = 142, p < 0.05), 15.9% (n = 72, p = ns), 6.8% (n = 31, p = ns), 10.8% (n = 49, p < 0.05), 2% (n = 9, p < 0.05) and 2.2% (n = 10) in men, respectively. In the women were 21.8% of ovarian metastases (n = 80). Treatment received by patients with stage IV was: chemotherapy in 278 women (72%) versus 334 men (71%) and the best supportive care in 83 women (21.5%) versus 112 men (23.8%).

Conclusion

About 44% of the gastric cancer were in women, more younger and with high percentages of poor prognosis factors: diffuse type adenocarcinoma, signet ring cell, poorly differentiated and stage IV with peritoneal carcinomatosis, ascites and metastasis to ovaries and liver as the main sites. The adenocarcinoma in esophageal gastric junction was more common in men.